menu
    • menu
    [{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Melanoma Research Foundation Breakthrough Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Voruciclib","moa":"Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Melanoma Research Foundation Breakthrough Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Melanoma Research Foundation Breakthrough Consortium"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Dana-Farber Cancer Institute | Norris Cotton Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Voruciclib","moa":"Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Enterprises Limited \/ Dana-Farber Cancer Institute | Norris Cotton Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Enterprises Limited \/ Dana-Farber Cancer Institute | Norris Cotton Cancer Center"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Preclinical","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Voruciclib","moa":"Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Voruciclib

    Menu

    Voruciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma Updates Study Of Oral CDK9 Inhibitor Voruciclib with Venetoclax

                            Details : ME-522 (voruciclib), a selective CDK9 inhibitor, is being evaluated with venetoclax for the treatment of relapsed and refractory acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Voruciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Co...

                            Details : ME-522 (voruciclib) is an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor with potential to treat Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : Voruciclib,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma Reports Preclinical Data Shwing Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhib...

                            Details : Voruciclib and support its potential as a therapeutic option for KRAS mutated cancers in combination with direct inhibitors of KRAS.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2021

                            Lead Product(s) : Voruciclib,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

                            Details : Voruciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Follicular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2018

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Piramal Enterprises Limited

                            India arrow
                            AAPS
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

                            Details : P1446A-05 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 17, 2014

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Dana-Farber Cancer Institute | Norris Cotton Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Piramal Enterprises Limited

                            India arrow
                            AAPS
                            Not Confirmed

                            Piramal Enterprises Limited

                            India arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Melanoma Research Foundation Breakthrough Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperabl...

                            Details : P1446A-05 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 26, 2013

                            Lead Product(s) : Voruciclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Melanoma Research Foundation Breakthrough Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth